Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers

Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market

More from Archive

More from Scrip